Table 2.
The sample divided in a vaccinated and unvaccinated group.
| Variable | Vaccinated (n = 113) |
Unvaccinated (n = 81) |
p-Value |
|---|---|---|---|
| Female n, (%) | 74 (65.5) | 54 (66.7) | 0.86 |
| Age (y), mean | 43 | 45 | 0.25 |
| EDSS, mean (range) | 1.6 (0–8.5) | 1.9 (0–7.5) | 0.39 |
| MS type | |||
| RRMS, n (%) | 105 (92.9) | 74 (91.4) | 0.69 |
| PPMS, n (%) | 1 (0.9) | - | 0.39 |
| SPMS, n (%) | 7 (6.2) | 7 (8.6) | 0.52 |
| Total comorbidities, n (%) | 61 (54) | 40 (49.4) | 0.53 |
| Autoimmune comorbidity n, (%) |
12 (19.7) | 3 (7.5) | 0.07 |
| Non-autoimmune comorbidity n, (%) | 49 (80.3) | 37 (92.5) | 0.75 |
| DMT for MS n, (%) | |||
| Interferon | 13 (11.5) | 16 (19.8) | 0.07 |
| Ocrelizumab | 9 (8) | 7 (8.6) | 0.87 |
| Glatiramer acetate | 3 (2.6) | 6 (7.4) | 0.12 |
| Fingolimod | 8 (7.1) | 6 (7.4) | 0.93 |
| Cladribrine | 4 (3.5) | 5 (6.2) | 0.38 |
| Dimethyl fumarate | 28 (24.8) | 17 (21) | 0.54 |
| Natalizumab | 28 (24.8) | 9 (11.1) | 0.01 |
| Teriflunomide | 17 (15) | 13 (16) | 0.85 |
| Azathioprine | 1 (0.9) | - | 0.39 |
| Alemtuzumab | 1 (0.9) | - | 0.39 |
| No therapy | 1 (0.9) | 2 (2.5) | 0.38 |
|
Patients with Relapse before vaccination
(up to 12 months) |
|||
| YES | 13 (11.5) | 6 (7.4) | 0.34 |
| NO | 100 (88.5) | 75 (92.6) |
MS: Multiple Sclerosis; RRMS: Relapsing Remitting Multiple Sclerosis; SPMS: Secondary Progressive Multiple Sclerosis; PPMS: Primary Progressive Multiple Sclerosis; EDSS: Expanded Disability Status Scale; DMT: disease modifying therapy.